1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,119 | 0,135 | 19:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 27.05. | Viva Biotech: From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery | 552 | PR Newswire | SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated... ► Artikel lesen | |
| 26.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
| 08.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 22.04. | VIVA BIOTECH (01873): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 07.04. | Fifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturing | 572 | PR Newswire | Delivering Continuity in a Changing LandscapeClients across the region view Viva Biotech not just as a service provider, but as a consistent, reliable partner and collaborator, an extension of their... ► Artikel lesen | |
| 30.03. | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | 362 | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 30.03. | Viva Biotech Holdings Full Year Profit Climbs | 2 | RTTNews | ||
| 30.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 18.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 17.03. | Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA | 554 | PR Newswire | SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting... ► Artikel lesen | |
| 16.02. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 16.02. | VIVA BIOTECH (01873): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 29.01. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL | 1 | HKEx | ||
| 05.01. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | - | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,265 | -2,33 % | EILMELDUNG bei Valneva: Der Kurs nähert sich einer gefährlichen Marke - So reagieren erfahrene Anleger jetzt | ||
| NOVONESIS | 50,90 | +4,28 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 213,40 | -0,51 % | Genmab A/S: Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress | Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,620 | -1,36 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| BEONE MEDICINES LTD ADR | 228,00 | -3,39 % | BeOne Medicines Ltd.: BeOne Medicines präsentiert auf der ASCO 2026 neue Daten zur Beschleunigung seiner Pipeline für solide Tumoren | Vorträge und Posterpräsentationen decken drei Schwerpunktprogramme in den Bereichen Brust-, gynäkologische und gastrointestinale Krebserkrankungen ab, die sich rasch in Richtung der entscheidenden... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,310 | 0,00 % | Börsenrotation ohne KI! Jetzt 100 % mit MustGrow, Bayer und Novo Nordisk, Achtung bei K+S | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Perspektivenwechsel bleibt das Gebot der Stunde. Denn gestern tagte die EZB zur aktuellen Lage bei Inflation und Zinsniveau. Mit einer... ► Artikel lesen | |
| SINO BIOPHARM | 0,487 | -0,85 % | SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN | ||
| VERICEL | 32,000 | +2,56 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,380 | -3,64 % | Moleculin Biotech, Inc.: Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML | ||
| SENSEI BIOTHERAPEUTICS | 12,800 | -1,54 % | SelfCare Sensei, LLC: Wellbeing Educator and Martial Artist Jan Raeder Officially Launches Strive for M.O.R.E., the Book That Found 400 Readers Before It Ever Had a Launch | After three decades on the mat and a master's in wellbeing education, Raeder is done watching people settle for bubble baths when the science offers something betterPOTTERSVILLE, N.Y., June... ► Artikel lesen | |
| ZAI LAB LTD ADR | 14,000 | -2,10 % | Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak | ||
| BIOXCEL THERAPEUTICS | 0,976 | +1,67 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 5,306 | -0,11 % | H.C. Wainwright lowers Regenxbio stock price target on trial data | ||
| AKEBIA | 0,806 | -0,42 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors | CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics- , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 11,400 | +8,57 % | Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA | MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08,... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,007 (+5,69 %) liegt der Kurs bei 0,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.